Oncology Venture has USD 8.7 million deficit after nine months
Biotech company Oncology Venture has significantly increased its deficit in the third quarter, and for the first three quarters as a whole, but the company's finances are comfortable going into 2020, says the new finance director.
Cancer company Oncology Venture, which is the result of a May 2018 merger between the Medical Prognosis Institute and Oncology Venture Sweden, has been on a spending spree in July, August and September.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
.jpg)
